Literature DB >> 31314915

Crosstalk between Cdk5/p35 and ERK1/2 signalling mediates spinal astrocyte activity via the PPARγ pathway in a rat model of chronic constriction injury.

Yu Zhong1, Jialin Chen1, Jing Chen1, Yanhua Chen2, Li Li1, Yubo Xie1.   

Abstract

The specific mechanisms underlying cyclin-dependent kinase 5 (Cdk5)-mediated neuropathic pain at the spinal cord level remain elusive. The aim of the present study was to explore the role of crosstalk between Cdk5/p35 and extracellular signal-regulated kinase 1/2 (ERK1/2) signalling in mediating spinal astrocyte activity via the PPARγ pathway in a rat model of chronic constriction injury (CCI). Here, we quantified pain behaviour after CCI; detected the localization of p35, Cdk5, phosphorylated ERK1/2 (pERK1/2), phosphorylated peroxisome proliferator-activated receptor γ (pPPARγ), neuronal nuclei (a neuronal marker), glial fibrillary acidic protein (GFAP, an activated astrocyte marker) and ionized calcium binding adaptor molecule 1 (a microglial marker) in the dorsal horn using immunofluorescence; measured the protein levels of Cdk5, p35, pERK1/2, pPPARγ and GFAP using western blot analysis; and gauged the enzyme activity of Cdk5/p35 kinase using a Cdk5/p35 kinase activity assay kit. Tumour necrosis factor-α, interleukin (IL)-1β and IL-6 levels were measured using enzyme-linked immunosorbent assay (ELISA). Ligation of the right sciatic nerve induced mechanical allodynia; thermal hyperalgesia; and the time-dependent upregulation of p35, pERK1/2 and GFAP and downregulation of pPPARγ. p35 colocalized with Cdk5, pERK1/2, pPPARγ, neurons and astrocytes but not microglia. Meanwhile, intrathecal injection of the Cdk5 inhibitor roscovitine, the mitogen-activated ERK kinase (MEK) inhibitor U0126 and the PPARγ agonist pioglitazone prevented or reversed behavioural allodynia, increased pPPARγ expression, inhibited astrocyte activation and alleviated proinflammatory cytokine (tumour necrosis factor-α, IL-1β, and IL-6) release from activated astrocytes. Furthermore, crosstalk between the Cdk5/p35 and ERK1/2 pathways was observed with CCI. Blockade of either Cdk5/p35 or ERK1/2 inhibited Cdk5 activity. These findings indicate that spinal crosstalk between the Cdk5/p35 and ERK1/2 pathways mediates astrocyte activity via the PPARγ pathway in CCI rats and that targeting this crosstalk could be an effective strategy to attenuate CCI and astrocyte-derived neuroinflammation.
© 2019 International Society for Neurochemistry.

Entities:  

Keywords:  Cdk5/p35; ERK1/2; GFAP; PPARγ; neuroinflammation; neuropathic pain

Year:  2019        PMID: 31314915     DOI: 10.1111/jnc.14827

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  Roles of Phosphorylation of N-Methyl-D-Aspartate Receptor in Chronic Pain.

Authors:  Liangyu Pan; Tiansheng Li; Rui Wang; Weiheng Deng; Huangsheng Pu; Meichun Deng
Journal:  Cell Mol Neurobiol       Date:  2022-01-15       Impact factor: 5.046

2.  The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy.

Authors:  D F S Santos; R R Donahue; D E Laird; M C G Oliveira; B K Taylor
Journal:  Neuropharmacology       Date:  2021-11-29       Impact factor: 5.250

3.  The Cannabidiol Analog PECS-101 Prevents Chemotherapy-Induced Neuropathic Pain via PPARγ Receptors.

Authors:  Nicole Rodrigues Silva; Francisco Isaac Fernandes Gomes; Alexandre Hashimoto Pereira Lopes; Isadora Lopes Cortez; Jéssica Cristina Dos Santos; Conceição Elidianne Aníbal Silva; Raphael Mechoulam; Felipe Villela Gomes; Thiago Mattar Cunha; Francisco Silveira Guimarães
Journal:  Neurotherapeutics       Date:  2021-12-13       Impact factor: 6.088

4.  Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model.

Authors:  Yasunori Haranishi; Koji Hara; Tadanori Terada
Journal:  Pharmacol Rep       Date:  2021-03-30       Impact factor: 3.024

5.  Long-Term Continuous Cervical Spinal Cord Stimulation Exerts Neuroprotective Effects in Experimental Parkinson's Disease.

Authors:  Ken Kuwahara; Tatsuya Sasaki; Takao Yasuhara; Masahiro Kameda; Yosuke Okazaki; Kakeru Hosomoto; Ittetsu Kin; Mihoko Okazaki; Satoru Yabuno; Satoshi Kawauchi; Yousuke Tomita; Michiari Umakoshi; Kyohei Kin; Jun Morimoto; Jea-Young Lee; Naoki Tajiri; Cesar V Borlongan; Isao Date
Journal:  Front Aging Neurosci       Date:  2020-06-16       Impact factor: 5.750

Review 6.  Cellular and Molecular Mechanisms of R/S-Roscovitine and CDKs Related Inhibition under Both Focal and Global Cerebral Ischemia: A Focus on Neurovascular Unit and Immune Cells.

Authors:  Lucas Le Roy; Anne Letondor; Cloé Le Roux; Ahmed Amara; Serge Timsit
Journal:  Cells       Date:  2021-01-08       Impact factor: 6.600

7.  PPAR γ Prevents Neuropathic Pain by Down-Regulating CX3CR1 and Attenuating M1 Activation of Microglia in the Spinal Cord of Rats Using a Sciatic Chronic Constriction Injury Model.

Authors:  Xilei Li; Qulian Guo; Zhi Ye; E Wang; Wangyuan Zou; Zhihua Sun; Zhenghua He; Tao Zhong; Yingqi Weng; Yundan Pan
Journal:  Front Neurosci       Date:  2021-03-24       Impact factor: 4.677

8.  New Insight of Circular RNAs' Roles in Central Nervous System Post-Traumatic Injury.

Authors:  Lvwan Xu; Xin Ye; Jinjie Zhong; Ying-Ying Chen; Lin-Lin Wang
Journal:  Front Neurosci       Date:  2021-03-23       Impact factor: 4.677

Review 9.  The role of cyclin-dependent kinase 5 in neuropathic pain.

Authors:  Kimberly Gomez; Tissiana G M Vallecillo; Aubin Moutal; Samantha Perez-Miller; Rodolfo Delgado-Lezama; Ricardo Felix; Rajesh Khanna
Journal:  Pain       Date:  2020-12       Impact factor: 7.926

10.  VGLUT2/Cdk5/p25 Signaling Pathway Contributed to Inflammatory Pain by Complete Freund's Adjuvant.

Authors:  Yuwen Tang; Zhiyou Peng; Shoujun Tao; Jianliang Sun; Wenyuan Wang; Xuejiao Guo; Gonglu Liu; Xianzhe Luo; Yuan Chen; Yue Shen; Haixiang Ma; Peng Xu; Qinghua Li; Honghai Zhang; Zhiying Feng
Journal:  Pain Res Manag       Date:  2020-02-29       Impact factor: 3.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.